What is Wharton's jelly?
The umbilical cord is the tissue that connects the developing fetus to the placenta. Anatomically it contains three vessels — one umbilical vein that carries oxygenated blood from the placenta to the fetus, and two umbilical arteries that return deoxygenated blood from the fetus back to the placenta. The connective tissue that cushions and surrounds these vessels is called Wharton's jelly, named after the 17th-century English physician Thomas Wharton who first described it in 1656.
Histologically, Wharton's jelly is a gelatinous mucous connective tissue rich in glycosaminoglycans (especially hyaluronic acid), collagen fibers, and a population of stromal cells with strong mesenchymal characteristics. It is biologically young — at the time of birth, the cord has been functioning for nine months — and it is anatomically distinct from cord blood. Cord blood contains hematopoietic stem cells (used for transplants in hematologic disease). Wharton's jelly contains mesenchymal stem cells (used for tissue repair, immunomodulation, and inflammation control). These are two different populations with two different clinical uses, and the distinction matters when comparing protocols.
When a delivery team and the family consent to donation, Wharton's jelly can be isolated from the cord segment between the umbilical artery and the umbilical vein. The remaining tissue would otherwise be discarded after birth. This anatomical accessibility — without any invasive procedure to the mother or the newborn — is one of the reasons UC-MSCs became a preferred allogeneic source in modern stem-cell laboratories.
Why UC-MSCs are preferred over older sources
Mesenchymal stem cells can be isolated from bone marrow, adipose tissue, dental pulp, placenta, and umbilical cord. Each source produces cells that meet the formal definition of an MSC, but the cells differ meaningfully in yield, proliferation, immunological profile, and how invasive the donation procedure is. Across the last decade of published comparative data, UC-MSCs have moved to the front of the line for several reasons.
- High yield per donation. A single umbilical cord delivers millions of viable MSCs per gram of Wharton's jelly. A bone-marrow aspirate from an adult donor yields orders of magnitude fewer cells per volume, with significant inter-donor variability. UC-MSCs scale predictably.
- Naïve cells with high proliferative capacity. Cells isolated at birth have not accumulated decades of replicative wear, telomere shortening, or environmental insults. They divide more readily in culture, reach therapeutic doses faster, and demonstrate stronger paracrine activity in preclinical assays than adult-derived MSCs.
- Low immunogenicity. UC-MSCs express low levels of HLA class I and minimal HLA class II, which is the molecular basis for their immunoprivileged behavior. In practice this means allogeneic UC-MSC preparations can be administered without HLA matching in carefully screened protocols, and rejection events are rare in published cohorts.
- No painful or invasive donor procedure. Bone marrow aspirate requires general or regional anesthesia and a needle puncture of the iliac crest. Adipose-derived MSCs require liposuction. Wharton's jelly is obtained from tissue that would otherwise be discarded after delivery — the mother undergoes no additional procedure to donate.
- Strong immunomodulatory and paracrine profile. UC-MSCs secrete a robust panel of cytokines (IL-10, TGF-β, IDO), growth factors (HGF, VEGF, FGF-2), and extracellular vesicles. The combination supports their use as an immunomodulatory and tissue-supportive agent rather than a simple cell-replacement product.
- Standardized lot characterization. Because UC-MSCs come from a single donor and a single processing event, every lot can be characterized with flow cytometry, viability assays, and contamination panels before release. The variability that plagues bedside autologous preparations is moved upstream into a controlled laboratory environment.
Ethical sourcing — consent, traceability, and discarded tissue
Umbilical-cord stem cells are not embryonic stem cells. They are obtained from the post-natal umbilical cord, which is biological waste after a routine delivery. Mothers (and, where applicable, both parents) provide explicit, informed, written consent for tissue donation before the delivery. Consent is voluntary, can be withdrawn at any point before processing, and is separate from any medical decisions about the delivery itself. Donation does not change the clinical care the mother or newborn receive in any way.
Most ethical-grade UC-MSC programs source tissue specifically from planned C-section deliveries with consenting mothers. The reason is procedural: a scheduled C-section delivery occurs under controlled sterile field conditions, the cord can be handled without contamination, and the cold chain to the processing laboratory can be planned in advance. Vaginal-delivery cord tissue is biologically equivalent but harder to capture under research-grade sterile conditions in a hospital setting.
After collection, every donation is anonymized, assigned a unique lot identifier, and traceable end-to-end: hospital of origin, date of collection, donor screening results, processing facility, expansion passage number, viability at release, and clinic of administration. A reputable supplying laboratory can produce a Certificate of Analysis (CoA) for any given lot on request, and a reputable clinic will not infuse cells from a lot it cannot trace.
The ethical floor is straightforward: no donor is paid for the tissue beyond reasonable expense reimbursement permitted by local law; donor identity is protected; consent is documented; and the tissue would have been discarded had the family declined to donate. International standards from ISCT, AABB, and equivalent regional bodies converge on these same requirements.
Donor screening protocol — what every donor is tested for
Donor screening is the strongest safety filter in allogeneic stem-cell therapy. A compliant screening package, performed at the laboratory that processes the tissue (not at the receiving clinic), covers four pillars: a comprehensive donor health questionnaire, infectious disease serology, a laboratory panel, and a documented chain of custody.
- Donor health questionnaire. Personal and family medical history covering hereditary disease, genetic conditions, autoimmune disease, malignancy, transmissible illness exposure, lifestyle factors, recent travel to areas with endemic infections, recent vaccinations, and current medications. The questionnaire is administered before consent is signed and forms part of the permanent donor record.
- Infectious disease serology. Mandatory testing on every donor: HIV-1 and HIV-2 (antibody and NAT), Hepatitis B virus (HBsAg, anti-HBc, HBV NAT), Hepatitis C virus (anti-HCV and HCV NAT), Syphilis (treponemal test), CMV (anti-CMV IgM/IgG), and HTLV-I/II. Additional regional screens — Chagas disease, West Nile virus, Zika, malaria — are added based on donor geography and travel history.
- Laboratory panel and tissue testing. Complete blood count, basic metabolic panel, blood typing, and direct microbiological testing of the tissue itself (aerobic and anaerobic bacterial culture, fungal culture, mycoplasma) at multiple points in processing. Cells are not released for clinical use until contamination testing returns clean at the final passage.
- Chain of custody. Time-stamped documentation from collection through cryopreservation through release. Every transfer is signed, temperature-monitored, and recorded in a tamper-evident system. The receiving clinic should be able to follow the chain backward from infusion to donor on request.
A clinic that cannot produce — or refuses to produce — the screening documentation for a given lot is asking the patient to trust an unverifiable claim. Ask for a Certificate of Analysis. A compliant supplying laboratory issues one for every lot it releases.
Processing and expansion — sterile lab, GMP-aligned
Once tissue arrives at the processing facility — typically within hours of delivery, on a validated cold chain — Wharton's jelly is dissected from the cord segment, enzymatically or explant-cultured to release the mesenchymal cell population, and seeded into culture flasks in a defined medium. Early passages are characterized for morphology, adherence, and surface marker profile before being expanded further.
Modern processing aligns with Good Manufacturing Practice (GMP) principles: dedicated clean rooms with controlled HEPA-filtered air, gowned operators following written SOPs, environmental monitoring, and lot-by-lot release testing. In Mexico, the laboratories that supply cells to clinics operate under COFEPRIS authorizations specific to tissue and cellular processing, with additional sector standards under the relevant NOMs and adherence to international guidance where applicable.
Release testing covers three things. First, viability — ISCT guidance calls for ≥70%, and high-quality laboratories typically release at ≥95% viability at the final passage. Second, identity — flow cytometry confirming the MSC immunophenotype: positive for CD73, CD90, and CD105 (≥95% of the population), negative for the hematopoietic markers CD34, CD45, CD11b, CD14, CD19, HLA-DR (≤2% of the population). Third, function — assays demonstrating that the cells retain trilineage differentiation potential (osteogenic, adipogenic, chondrogenic) under standard inducing conditions.
Cells are then cryopreserved in defined freezing medium, banked, and released as needed for clinical use. The receiving clinic should know — and the patient should be able to ask — at what passage number the cells were cryopreserved, what the post-thaw viability was, and which lot specifically is being administered.
Allogeneic safety — what published cohorts show
The biological basis for the safety of allogeneic UC-MSC infusions is well established. Low HLA class I expression and minimal HLA class II expression mean these cells do not present strong immunological targets in the recipient. In practice this has translated into reassuring safety data across a growing body of published cohorts spanning orthopedic, autoimmune, and inflammatory indications.
The most common adverse events reported in the literature are transient and minor: low-grade fever in the hours after infusion, mild headache, transient chills, and short-lived injection-site discomfort for joint-injected protocols. Serious adverse events — clinically significant immune reactions, infection traced to the cell product, ectopic tissue formation, or tumor formation — have remained rare across thousands of treated patients in registries that publish safety outcomes. The most catastrophic reported events in regenerative medicine have generally traced back to poorly characterized autologous adipose-derived preparations administered outside any sterile chain, not to well-screened allogeneic UC-MSCs from licensed laboratories.
Two important caveats. First, safety is a population-level statement; individual response varies and the clinical team must screen for contraindications before any infusion. Second, the safety floor is only as strong as the supply chain: an unscreened or contaminated lot can cause serious harm regardless of source. This is why the screening, processing, and characterization standards described above are non-negotiable — not optional.
How UC-MSCs compare to adipose- and bone-marrow-derived MSCs
Each MSC source has legitimate clinical uses; none is universally superior for every indication. The table below summarizes the practical differences a patient should understand before a clinic recommends one source over another.
| Attribute | UC-MSC (Wharton's jelly) | Adipose (AD-MSC) | Bone marrow (BM-MSC) |
|---|---|---|---|
| Donor procedure | None for mother/newborn — tissue otherwise discarded | Liposuction under local or general anesthesia | Aspiration from iliac crest under anesthesia |
| Source type | Allogeneic (donor) | Typically autologous, sometimes allogeneic | Typically autologous, sometimes allogeneic |
| Cell age (biological) | Naïve — birth-derived, no replicative wear | Donor age — accumulated environmental insults | Donor age — declining proliferation with age |
| Yield per donation | High and predictable | Moderate to high, donor-dependent | Low to moderate, donor-dependent |
| Proliferative capacity | Very high in culture | Moderate | Lower, declines with age |
| Immunogenicity | Low (HLA-low, immunoprivileged) | Low when autologous; moderate allogeneic | Low when autologous; moderate allogeneic |
| Standardized dosing | Yes — lot-characterized banking | Variable, bedside preparations | Variable, bedside preparations |
| Common clinical uses | Systemic immunomodulation, multi-joint, IV anti-inflammatory | Local injection, orthopedic, aesthetic | Orthopedic, hematologic (BMAC distinct from BM-MSC) |
Neither table nor any clinic conversation replaces a personalized medical evaluation. A responsible physician will recommend the source most appropriate to the specific diagnosis, route of administration, and patient profile — not the source with the strongest marketing.
Frequently asked questions
Yes, when sourced under explicit, informed, written consent from the mother. The umbilical cord is biological waste after delivery — Wharton's jelly is obtained from tissue that would otherwise be discarded, without any additional procedure on the mother or the newborn. Cord stem cells are not embryonic stem cells; they are post-natal stromal cells from a routine delivery. Reputable programs document consent, anonymize the donor, and never pay beyond reasonable expense reimbursement.
Revisado por Dra. Claudia Labastida Salazar · 2026-05-27
UC-MSCs express low HLA class I and minimal HLA class II, which makes them immunoprivileged. In published cohorts, allogeneic UC-MSC infusions have not required HLA matching and rejection events have remained rare across thousands of treated patients. Transient minor effects — low-grade fever, mild headache, transient chills — are the most commonly reported, and serious immune reactions are uncommon when cells come from a screened, licensed laboratory. As with any biologic, the clinical team must screen for contraindications before any infusion.
Revisado por Dra. Claudia Labastida Salazar · 2026-05-27
The donor is a consenting mother whose delivery — typically a planned C-section under controlled sterile field — yields the umbilical cord from which Wharton's jelly is isolated. Screening is performed at the processing laboratory and covers a donor health questionnaire, infectious disease serology (HIV, HBV, HCV, syphilis, CMV, HTLV at minimum, plus regional screens), routine laboratory panel, direct microbiological testing of the tissue, and a documented chain of custody. A Certificate of Analysis is issued for every lot.
Revisado por Dra. Claudia Labastida Salazar · 2026-05-27
Yes — private cord-tissue banking services do exist and are offered at the time of delivery for the patient's own future use (autologous) or, in some programs, for sibling use. This is a separate decision from allogeneic UC-MSC therapy. If you are a new or expectant parent, talk to your obstetric team well before delivery — private banking requires advance consent, contracting, and a collection kit at the hospital. For adults seeking treatment now, autologous cord banking is not an option (your own cord tissue was not preserved at birth in most cases), which is one of the reasons allogeneic UC-MSC protocols exist.
Revisado por Dra. Claudia Labastida Salazar · 2026-05-27
Pricing depends on diagnosis, route of administration, total cell dose, and whether the protocol is single-session or multi-session. As a general range, COFEPRIS-aligned UC-MSC protocols in Cancún commonly fall in the $5,000–$15,000 USD range inclusive of physician fees and laboratory costs, compared with $15,000–$50,000+ for equivalent allogeneic preparations where they can be accessed in the United States. Every quote should be in writing, on letterhead, and itemized — see our pricing page for current ranges.
Revisado por Dra. Claudia Labastida Salazar · 2026-05-27
Yes. The laboratories that process Wharton's jelly into clinical UC-MSC preparations operate under COFEPRIS authorizations specific to tissue and cellular processing. The clinics that administer them operate under their own COFEPRIS Aviso de Funcionamiento and Aviso de Publicidad, and the treating physician must hold an active cédula profesional. The full regulatory framework is described on our safety and COFEPRIS page.
Revisado por Dra. Claudia Labastida Salazar · 2026-05-27
UC-MSCs are biologically younger, available in higher and more predictable yields, and can be standardized lot-by-lot in a regulated laboratory. Autologous adipose and bone marrow preparations avoid the allogeneic question entirely but vary by donor age and yield, and bedside preparations are harder to characterize. Neither is universally better — the right choice depends on diagnosis, route of administration, and patient profile. A responsible clinic recommends the source appropriate to the case, not the source with the strongest marketing.
Revisado por Dra. Claudia Labastida Salazar · 2026-05-27
No. Allogeneic culture-expanded MSC preparations — including UC-MSCs — sit inside the FDA's IND pathway in the United States, which means they can only be administered inside registered clinical trials in that jurisdiction. The FDA framework does not apply outside US jurisdiction. In Mexico, equivalent preparations are administered under COFEPRIS-regulated medical practice, provided the clinic, the supplying laboratory, and the physician all hold the correct authorizations.
Revisado por Dra. Claudia Labastida Salazar · 2026-05-27
Information for educational purposes only. Stem cell therapy is investigational for many indications; individual outcomes vary and depend on diagnosis, prior treatments, and overall health. Nothing on this page is a guarantee of result, and no protocol should be initiated without a personalized medical evaluation by a licensed physician.